34 累计需求单数
¥1,355,097.0 累计需求金额
0 违规次数

罕见癌症研究基金会(RCRF)需求一种新方法在体内原发性肿瘤中建立新的细胞株

悬赏
未托管赏金
¥600000.00
  1. 发布需求
  2. 药智客交稿
  3. 任务主选稿中
  4. 选满结束
  1. 任务结束
任务结束
交易模式:
多人中标
赏金分配:
计件,每个¥100000,已选0个,还需要6个
具体要求:
罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展,即在体内原发性肿瘤中建立新的细胞株。
      为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元,开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下:https://www.innocentive.com/ar/challenge/9933756
The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog.

This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery.


Source: InnoCentive      Challenge ID: 9933756
 
  Challenge Overview
This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use.

To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual creators are eligible for one (the first cell line from either disease) or up to ten prizes (the first, second, third, fourth, and fifth cell lines from both diseases). To be eligible for the prize(s), the submitted cell lines must be:

Approved by the Caring for Carcinoid Foundation, according to the criteria specified in the Detailed Description & Requirements, and 
Deposited into the ATCC repository for unrestricted distribution to qualified investigators under an agreement approved by the Caring for Carcinoid Foundation. 
Discover how to submit your cell lines in the Detailed Description & Requirements of the Challenge.



				
2015-07-16 15:12
0条新稿件,点击看看
还没有人交稿哦!
赶快点击交稿吧~

当前为付费需求,赏金分配方式:计件,合格一个支付一个。

发布者在发布需求时设定需要的稿件个数和单价,选标时在众多参与中挑选合格的稿件,合格一个支付一个,即时到账。

托管赏金,保证资金安全:

通过药智网托管赏金,全面保障买家的资金安全。

买家先托管赏金到药智网,药智网担保资金安全;买家对威客工作满意后,再通知药智网打款给威客。

流程说明:

发布需求

点击“发布需求”按钮,按照流程引导,将需求详情、具体要求描述清楚,发布到药智网的药智汇平台。

托管赏金

为征集到满意稿件,任务主须做好“赏金预算”,并将赏金托管到药智网指定账户,打消药智客的顾虑,激励药智客积极参与需求挑战。

药智客参与

任务主托管赏金后,所发布的需求显示“赏金已托管”字样。只有托管了悬赏金的需求,能够鼓舞众多的药智客参与,获取到满意的稿件!

选择满意合格

雇佣者会在众多参与中选择满意的合格,合格一个支付一个,即时到账。

类似的需求

    加载数据中...

该需求者还有这些需求

    加载数据中...

推荐需求

    加载数据中...
感兴趣,就投稿吧!投的越早,中标几率就越大! 收藏
扫一扫,关注药智汇微信
及时获得最新药智汇信息

2014 药智再发力 我们换装了!!

为了让您有更好的体验,药智对用户体系和产品进行了全新升级!

我要看看